Edwards Lifesciences Corporation (EW) experienced a decrease of 5.74% in the aftermarket after the company announced fourth-quarter results. However, the last trading session concluded at $108.63 with a decrease of 0.79%.
Fourth Quarter Results by EW – What’s up?
EW reported fourth-quarter results on 26th January 2022. The company stated that they have seen a 19% increase in the 2021 sales. Not only this but Q4 sales also inclined to $1.33 billion with the growth of almost 12%. Moreover, the selling, general, and administrative expenses totaled $424 million, $339 million more than that of the previous year. In comparison to the COVID, this growth was motivated by the return of medical congresses and commercial activities. Last but not the least, the research and development expenses also increased 19 percent to $233 million.
So what?
EW sees even greater growth and progress in 2022. The business is optimistic about the continued spread of transcatheter-based therapies for the many structural heart patients who still require them, putting them in a good position for long-term success. As the world’s population ages and the cardiovascular disease continues to be the main cause of death, EW predicts that the chance to service patients will nearly double between now and 2028. Finally, the organization is optimistic about the possibility of a patient-centered innovation strategy to transform treatment.
FDA Approval for Sapien 3 – More About it
On 20th December 2021, EW announced that FDA has authorized the use of the Edwards SAPIEN 3 transcatheter valve. The FDA’s authorization of the SAPIEN 3 with Alterra is fantastic news for patients all over the world, including those who have had multiple surgeries to treat their congenital heart defects.
Moreover, the excellent results of SAPIEN 3 with Alterra will broaden the number of patients requiring pulmonary valve replacement. Lastly, this will lead to major improvements in quality of life as well as a decrease in the number of surgeries and treatments that a congenital heart patients will require during their lifespan.
